Latest:
Dr Ludmir on the Rationale For the EXTEND Trial in PDAC
Ethan B. Ludmir, MD, shares the rationale for and the outcomes derived from the EXTEND trial in oligometastatic pancreatic ductal adenocarcinoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Nicholas J. Short, MD
Latest:
Understanding How to Best Measure MRD Negativity in Ph+ ALL
The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.
Waddah Arafat, MD
Waddah Arafat, MD, is an associate professor of internal medicine and a member of the Division of Hematology and Oncology at the University of Texas (UT) Southwestern Medical Center; as well as medical director of the Clinical Cancer Informatics Program at the UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Latest:
Dr Arafat on Evolving Neoadjuvant Treatment Strategies in MIBC
Waddah Arafat, MD, discusses how the use of neoadjuvant chemotherapy in MIBC has changed relative to the addition of immunotherapy to this paradigm.
Catherine Lee, MD
Latest:
The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab: A Post Hoc Analysis of Agave-201
Dr. Catherine Lee presents a post-hoc analysis of the AGAVE-201 trial, demonstrating that axatilimab achieves consistent overall response rates in patients with chronic graft-versus-host disease regardless of prior lines of therapy, with rapid and durable responses, particularly following ruxolitinib, and a favorable safety profile.
Timothy Cloughesy, MD
Timothy F. Cloughesy, MD, is a professor and director in the Department of Neurology, Neurological Services, and the Neuro-Oncology Program; a physician in the Department of Neurology; a member of the Brain Research Institute; a member of Cancer Molecular Imaging, Nanotechnology, and Theranostics; and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center
Latest:
Dr Cloughesy on the FDA Approval of Dordaviprone for Diffuse Midline Glioma
Timothy F. Cloughesy, MD, discusses the FDA approval of dordaviprone for the treatment of patients with H3K27M-mutated diffuse midline glioma.
Michele Reni, MD
Michele Reni, MD, is a Specialist in Medical Oncology at the Department of Medical Oncology at the San Raffaele Research Hospital in Milan.
Latest:
Dr Reni on the Efficacy of Preoperative PAXG in Stage I to III PDAC
Michele Reni, MD, discusses the efficacy of pre-operative PAXG compared with modified FOLFIRINOX in stage I to III PDAC.
Christian Grohe, MD, Evangelical Lung Cancer Hospital
Latest:
The Evolving Treatment Landscape of Small Cell Lung Cancer
Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Tomasz Jankowski, MD, PhD
Tomasz Jankowski, MD, PhD, is the chair of the Department of Pneumology, Oncology and Allergology and an assistant professor in the Faculty of Medicine at the Medical University of Lublin.
Latest:
Dr Jankowski on the Telomere-Targeted Agent THIO With Cemiplimab in Advanced NSCLC
Tomasz Jankowski, MD, PhD, discusses THIO sequenced with cemiplimab for the third-line treatment of patients with ICI-resistant advanced NSCLC.
Sophie Paczesny, MD, PhD
Sophie Paczesny MD, PhD, is a professor in the Department of Microbiology and Immunology and co-leader of the Cancer Immunology Program at the Hollings Cancer Center at the Medical University of South Carolina.
Latest:
Dr Paczesny on ST2 as a Biomarker for Acute GVHD Risk Post-Transplant
Sophie Paczesny MD, PhD, discussed the ability of ST2 to predict the risk of developing aGVHD or death following transplant.